Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Taxes (2023 - 2025)

Vivos Therapeutics (VVOS) has disclosed Current Taxes for 3 consecutive years, with $727000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Taxes changed N/A to $727000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $727000.0, a N/A change, with the full-year FY2024 number at $481000.0, up 47.09% from a year prior.
  • Current Taxes was $727000.0 for Q3 2025 at Vivos Therapeutics, up from $631000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $727000.0 in Q3 2025 to a low of $327000.0 in Q4 2023.
  • A 3-year average of $539800.0 and a median of $533000.0 in 2025 define the central range for Current Taxes.
  • Biggest YoY gain for Current Taxes was 47.09% in 2024; the steepest drop was 47.09% in 2024.
  • Vivos Therapeutics' Current Taxes stood at $327000.0 in 2023, then soared by 47.09% to $481000.0 in 2024, then skyrocketed by 51.14% to $727000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Current Taxes are $727000.0 (Q3 2025), $631000.0 (Q2 2025), and $533000.0 (Q1 2025).